Boston Scientific (NYSE: BSX) reported Q4 EPS of $0.22, $0.01 better than the analyst estimate of $0.21. Revenue for the quarter came in at $1.89 billion versus the consensus estimate of $1.91 billion.

"2014 was another year of significant achievement for Boston Scientific," said Mike Mahoney, president and chief executive officer, Boston Scientific Corporation. "We strengthened our core businesses and invested in new technologies and global markets, which contributed to excellent results across our businesses and regions. Additionally, we expanded our operating margins and delivered double digit adjusted EPS growth. We look forward to the year ahead and bringing more innovative medical technologies and solutions to patients, physicians and hospitals."

For earnings history and earnings-related data on Boston Scientific (BSX) click here.